These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39055886)

  • 1. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma.
    Zhuang M; Zhang X; Li LU; Wen L; Qin J
    Oncol Res; 2024; 32(8):1347-1357. PubMed ID: 39055886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
    Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
    Cancer Sci; 2024 Jul; 115(7):2220-2234. PubMed ID: 38623968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
    Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
    J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
    Zhang X; Wang W; Mo S; Sun X
    Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma.
    Hu X; Zhang P; Li S; Zhang J; Wang D; Wang Z; Zhu L; Wang L
    J Transl Med; 2024 Jun; 22(1):593. PubMed ID: 38918793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
    Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
    Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
    Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
    Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC.
    Mo C; You W; Rao Y; Lin Z; Wang S; He T; Shen H; Li X; Zhang R; Li B
    Cell Mol Life Sci; 2024 Jul; 81(1):284. PubMed ID: 38967794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.